1. Assessment of Predictors for SARS-CoV-2 Antibodies Decline Rate in Health Care Workers after BNT162b2 Vaccination—Results from a Serological Survey.
- Author
-
Zacks, Nadav, Bar-Shai, Amir, Levi, Hezi, Breslavsky, Anna, Maayan, Shlomo, Evgenia, Tsyba, Feitelovich, Shlomo, Wand, Ori, Schaffer, Moshe, Sherer, Yaniv, Givaty, Gili, Tzurel Ferber, Anat, Michael, Tal, and Bilenko, Natalya
- Subjects
MEDICAL personnel ,CORONAVIRUS diseases ,COVID-19 ,COVID-19 vaccines ,VACCINATION ,SARS-CoV-2 - Abstract
Background: SARS-CoV-2 is a novel human pathogen causing Coronavirus Disease 2019 that has caused widespread global mortality and morbidity. Since health workers in Israel were among the first to be vaccinated, we had a unique opportunity to investigate the post-vaccination level of IgG anti-S levels antibodies (Abs) and their dynamics by demographic and professional factors. Methods: Prospective Serological Survey during December 2020–August 2021 at Barzilai Medical Center among 458 health care workers (HCW) followed for 6 months after the second BNT162b2 vaccine dose. Results: Antibody levels before the second dose, and 30, 90 and 180 days after were 57.1 ± 29.2, 223 ± 70.2, 172.8 ± 73.3 and 166.4 ± 100.7 AU/mL, respectively. From GEE analysis, females had higher Abs levels (β = 26.37 AU/mL, p = 0.002). Age was negatively associated with Abs, with a 1.17 AU/mL decrease for each additional year (p < 0.001). Direct contact with patients was associated with lower Abs by 25.02 AU/mL (p = 0.009) compared to working with no such contact. The average decline rate overall for the study period was 3.0 ± 2.9 AU/mL per week without differences by demographic parameters and was faster during the first 3 months after vaccination than in the subsequent 3 months. Conclusions: All demographic groups experienced a decline in Abs over time, faster during the first 3 months. Findings of overall Abs lower in males, workers with direct contact with patients, and older workers, should be considered for policy-making about choosing priority populations for additional vaccine doses in hospital settings. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF